• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Acrivon Therapeutics, Inc. - Common Stock (NQ: ACRV )

    6.630 -0.250 (-3.63%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 74,864
    Open 6.930
    Bid (Size) 6.270 (2)
    Ask (Size) 7.250 (1)
    Prev. Close 6.880
    Today's Range 6.600 - 6.990
    52wk Range 3.190 - 14.03
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024
    ACRV stock results show that Acrivon Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    +32.34%
    +32.34%
    1 Month
    -22.46%
    -22.46%
    3 Month
    +21.21%
    +21.21%
    6 Month
    +41.36%
    +41.36%
    1 Year
    -48.36%
    -48.36%

    More News

    Read More
    Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Via InvestorPlace
    Acrivon Therapeutics: Q4 Earnings Insights
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    Crude Oil Down Over 1%; Cognyte Software Shares Plummet
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Dow Dips 150 Points; Laser Photonics Shares Spike Higher
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Why Is Rail Vision (RVSN) Stock Up 17% Today?
    Via InvestorPlace
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost
    Via InvestorPlace
    Acrivon Therapeutics Stock Is Soaring Tuesday: What's Going On?
    Via Benzinga
    Dow Gains Over 50 Points; Neogen Posts Downbeat Earnings
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Acrivon Therapeutics Announces $130 Million Private Placement Financing
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    ACRV Stock Earnings: Acrivon Therapeutics Misses EPS for Q4 2023
    Via InvestorPlace
    Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
    From Acrivon Therapeutics, Inc
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.